Investigations of possible links between Alzheimer’s disease and type 2 diabetes mellitus by positron emission tomography: a systematic review

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Resumé

Purpose: To review published evidence of possible links between Alzheimer’s disease (AD) and type-2 diabetes mellitus revealed by positron emission tomography (PET). Methods: We searched online databases with keywords diabetes mellitus (DM), AD, and PET. We assessed the studies in terms of purpose, methodology, materials, and relationships between AD and DM suggested by PET imaging. Results: After removal of 142 duplicates, 227 hits yielded no more than 15 full-length publications, from which we excluded six for specific reasons. The remaining nine studies were not directly comparable because of differences of purpose, study design, material, and methods. Individual subject materials consisted of 4–154 patients in case–control (4), observational (4), and longitudinal (1) studies, the last including only four DM patients. Mean patient age was 76.4 years (range 45–90). In five studies, researchers examined regional cerebral glucose metabolism with 18F-fluorodeoxyglucose (FDG), in three studies, researchers imaged amyloid with PET, and in one study, they measured both glucose metabolism and amyloid deposition. All four studies of amyloid tracers led to the conclusion that amyloid deposition was unaffected by DM status. Evidence of insulin resistance and increased blood glucose was associated with decreased FDG accumulation in AD signature regions in DM patients. Conclusion: The relationships between DM and AD identified by PET appear to be independent of amyloid deposition and predominantly highlighted by reduced glucose metabolism, as suggested by four of the five glucose metabolism studies.

OriginalsprogEngelsk
TidsskriftClinical and Translational Imaging
Vol/bind7
Udgave nummer5
Sider (fra-til)327–336
ISSN2281-5872
DOI
StatusUdgivet - okt. 2019

Fingeraftryk

Type 2 Diabetes Mellitus
Diabetes Mellitus
Alzheimer Disease
Research Personnel
Fluorodeoxyglucose F18
Longitudinal Studies
Insulin Resistance
Publications
Databases

Citer dette

@article{688247776c2b48f6ace4e9cf1fa0c529,
title = "Investigations of possible links between Alzheimer’s disease and type 2 diabetes mellitus by positron emission tomography: a systematic review",
abstract = "Purpose: To review published evidence of possible links between Alzheimer’s disease (AD) and type-2 diabetes mellitus revealed by positron emission tomography (PET). Methods: We searched online databases with keywords diabetes mellitus (DM), AD, and PET. We assessed the studies in terms of purpose, methodology, materials, and relationships between AD and DM suggested by PET imaging. Results: After removal of 142 duplicates, 227 hits yielded no more than 15 full-length publications, from which we excluded six for specific reasons. The remaining nine studies were not directly comparable because of differences of purpose, study design, material, and methods. Individual subject materials consisted of 4–154 patients in case–control (4), observational (4), and longitudinal (1) studies, the last including only four DM patients. Mean patient age was 76.4 years (range 45–90). In five studies, researchers examined regional cerebral glucose metabolism with 18F-fluorodeoxyglucose (FDG), in three studies, researchers imaged amyloid with PET, and in one study, they measured both glucose metabolism and amyloid deposition. All four studies of amyloid tracers led to the conclusion that amyloid deposition was unaffected by DM status. Evidence of insulin resistance and increased blood glucose was associated with decreased FDG accumulation in AD signature regions in DM patients. Conclusion: The relationships between DM and AD identified by PET appear to be independent of amyloid deposition and predominantly highlighted by reduced glucose metabolism, as suggested by four of the five glucose metabolism studies.",
keywords = "Alzheimer’s disease, Dementia, Diabetes mellitus, Insulin resistance, Positron emission tomography, Systematic review",
author = "Reza Piri and Mohammad Naghavi-Behzad and Oke Gerke and H{\o}ilund-Carlsen, {Poul F.} and Vafaee, {Manouchehr Seyedi}",
year = "2019",
month = "10",
doi = "10.1007/s40336-019-00339-y",
language = "English",
volume = "7",
pages = "327–336",
journal = "Clinical and Translational Imaging",
issn = "2281-5872",
publisher = "Heinemann",
number = "5",

}

TY - JOUR

T1 - Investigations of possible links between Alzheimer’s disease and type 2 diabetes mellitus by positron emission tomography

T2 - a systematic review

AU - Piri, Reza

AU - Naghavi-Behzad, Mohammad

AU - Gerke, Oke

AU - Høilund-Carlsen, Poul F.

AU - Vafaee, Manouchehr Seyedi

PY - 2019/10

Y1 - 2019/10

N2 - Purpose: To review published evidence of possible links between Alzheimer’s disease (AD) and type-2 diabetes mellitus revealed by positron emission tomography (PET). Methods: We searched online databases with keywords diabetes mellitus (DM), AD, and PET. We assessed the studies in terms of purpose, methodology, materials, and relationships between AD and DM suggested by PET imaging. Results: After removal of 142 duplicates, 227 hits yielded no more than 15 full-length publications, from which we excluded six for specific reasons. The remaining nine studies were not directly comparable because of differences of purpose, study design, material, and methods. Individual subject materials consisted of 4–154 patients in case–control (4), observational (4), and longitudinal (1) studies, the last including only four DM patients. Mean patient age was 76.4 years (range 45–90). In five studies, researchers examined regional cerebral glucose metabolism with 18F-fluorodeoxyglucose (FDG), in three studies, researchers imaged amyloid with PET, and in one study, they measured both glucose metabolism and amyloid deposition. All four studies of amyloid tracers led to the conclusion that amyloid deposition was unaffected by DM status. Evidence of insulin resistance and increased blood glucose was associated with decreased FDG accumulation in AD signature regions in DM patients. Conclusion: The relationships between DM and AD identified by PET appear to be independent of amyloid deposition and predominantly highlighted by reduced glucose metabolism, as suggested by four of the five glucose metabolism studies.

AB - Purpose: To review published evidence of possible links between Alzheimer’s disease (AD) and type-2 diabetes mellitus revealed by positron emission tomography (PET). Methods: We searched online databases with keywords diabetes mellitus (DM), AD, and PET. We assessed the studies in terms of purpose, methodology, materials, and relationships between AD and DM suggested by PET imaging. Results: After removal of 142 duplicates, 227 hits yielded no more than 15 full-length publications, from which we excluded six for specific reasons. The remaining nine studies were not directly comparable because of differences of purpose, study design, material, and methods. Individual subject materials consisted of 4–154 patients in case–control (4), observational (4), and longitudinal (1) studies, the last including only four DM patients. Mean patient age was 76.4 years (range 45–90). In five studies, researchers examined regional cerebral glucose metabolism with 18F-fluorodeoxyglucose (FDG), in three studies, researchers imaged amyloid with PET, and in one study, they measured both glucose metabolism and amyloid deposition. All four studies of amyloid tracers led to the conclusion that amyloid deposition was unaffected by DM status. Evidence of insulin resistance and increased blood glucose was associated with decreased FDG accumulation in AD signature regions in DM patients. Conclusion: The relationships between DM and AD identified by PET appear to be independent of amyloid deposition and predominantly highlighted by reduced glucose metabolism, as suggested by four of the five glucose metabolism studies.

KW - Alzheimer’s disease

KW - Dementia

KW - Diabetes mellitus

KW - Insulin resistance

KW - Positron emission tomography

KW - Systematic review

U2 - 10.1007/s40336-019-00339-y

DO - 10.1007/s40336-019-00339-y

M3 - Review

AN - SCOPUS:85070723076

VL - 7

SP - 327

EP - 336

JO - Clinical and Translational Imaging

JF - Clinical and Translational Imaging

SN - 2281-5872

IS - 5

ER -